Kevin Carlson
Internal Medicine · Columbia, MDNPI 1811981905
Payments from drug & device makers
Across 82 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$259
- Pfizer$251
- AbbVie$134
- Radius Health, Inc.$124
- AstraZeneca$121
- Lilly USA, LLC$106
- plus $544 from 13 others
What the payments were for
- Food & beverage$1,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $259 |
| Pfizer | 13 | $251 |
| AbbVie(2 entities) | 7 | $134 |
| Radius Health, Inc. | 6 | $124 |
| AstraZeneca | 6 | $121 |
| Lilly USA, LLC | 6 | $106 |
| Exact Sciences | 4 | $95 |
| Johnson & Johnson(2 entities) | 5 | $79 |
| Novo Nordisk | 5 | $67 |
| Boehringer Ingelheim | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| GSK | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $35 |
| Novartis | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Phadia US Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,540 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $83,646 |
| MounjaroTirzepatide | 58 | $63,826 |
| OzempicSemaglutide | 39 | $49,301 |
| Repatha SureclickEvolocumab | 20 | $28,164 |
| JardianceEmpagliflozin | 13 | $17,396 |
| AmbienZolpidem Tartrate | 14 | $15,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,723 |
| Estradiol | 29 | $3,903 |
| Atorvastatin Calcium | 332 | $3,713 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $3,050 |
| SynthroidLevothyroxine Sodium | 32 | $2,783 |
| Rosuvastatin Calcium | 119 | $2,674 |
| Ipratropium Bromide | 72 | $2,442 |
| Bupropion XlBupropion Hcl | 63 | $2,239 |
| ValacyclovirValacyclovir Hcl | 42 | $2,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $251 | $85,074104 claims |
| Lilly USA, LLCMounjaro | $106 | $63,82658 claims |
| Novo NordiskOzempic | $67 | $49,30139 claims |
| Boehringer IngelheimJardiance | $57 | $17,39613 claims |
| GSKTrelegy Ellipta | $38 | $7,72313 claims |
| AbbVieSynthroid | $134 | $2,78332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Columbia
- Mark CorriereColumbia$402K
- Saba SheikhColumbia$342K
- William SawayColumbia$295K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.